<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910804</url>
  </required_header>
  <id_info>
    <org_study_id>BTHospital-N-005</org_study_id>
    <secondary_id>ZIAEB000073</secondary_id>
    <nct_id>NCT02910804</nct_id>
  </id_info>
  <brief_title>IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma</brief_title>
  <official_title>PET-NIRF Dual Modality Imaging Guiding Surgery in Patients With Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Biomedical Imaging and Bioengineering (NIBIB)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Key laboratory of molecular imaging Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label positron emission tomography/near infrared (PET/NIRF) study to
      investigate the imaging navigation performance and evaluation efficacy of dual modality
      imaging probe 68Ga-BBN-IRDye800CW in glioblastoma (GBM) patients. A single dose of
      40μg/111-148 Mega-Becquerel (MBq) and 1.0 mg/ml 68Ga-BBN-IRDye800CW will be injected
      intravenously before the operation and intraoperative respectively. Visual and
      semiquantitative method will be used to assess the PET images and real-time margins
      localization for surgical navigation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-invasive preoperative PET imaging evaluation and real-time fluorescence-guided surgery
      would be of great help in GBM patients. BBN, with the amino acid sequence of
      Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, has been extensively used for the development of
      molecular probes for the imaging of gastrin-releasing peptide receptor (GRPR), a member of
      the G protein-coupled receptor family of bombesin receptors that over-expressed in various
      types of cancer cells including glioblastoma multiforme. For interests in clinical
      translation of GRPR targeting dual modality probe, an open label dual modality imaging PET/
      NIFR study was designed to investigate the safety and imaging guiding performance of
      68Ga-BBN-IRDye800CW in patients with GBM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value of 68Ga-BBN-IRDye800CW in PET imaging of GBM</measure>
    <time_frame>1 year</time_frame>
    <description>The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in GBM will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Margin assessment of positive tumors in NIRF fluorescent-guided surgery</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>68Ga-BBN-IRDye800CW PET/NIRF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-BBN-IRDye800CW</intervention_name>
    <arm_group_label>68Ga-BBN-IRDye800CW PET/NIRF</arm_group_label>
    <other_name>BBN-IRDye800CW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/NIRF</intervention_name>
    <arm_group_label>68Ga-BBN-IRDye800CW PET/NIRF</arm_group_label>
    <other_name>Positron emission tomography/Near-infrared fluorescent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET/NIR fluorescent imaging-guided surgery</intervention_name>
    <arm_group_label>68Ga-BBN-IRDye800CW PET/NIRF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to provide a written informed consent

          -  MRI imaging and/or pathological evidence of Newly Diagnosed or recurrence GBM

        Exclusion Criteria:

          -  Consisted of conditions of mental illness

          -  Severe liver or kidney disease with serum creatinine &gt; 3.0 mg/dl (270 μΜ)

          -  Any hepatic enzyme level 5 times or more than normal upper limit

          -  Severe allergy or hypersensitivity to IV radiographic contrast

          -  Claustrophobia to accept the PET/CT scanning

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nan Ji, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tiantan Hospital, Capital Medical University Beijing 100050, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhaohui Zhu, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deling Li, MD</last_name>
    <email>ttyyneuroli@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingjing Zhang, MD.</last_name>
    <email>zhangjingjingtag@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deling Li, MD.</last_name>
      <phone>+86 10 69154196</phone>
      <email>ttyyneuroli@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Deling Li</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>GRPR</keyword>
  <keyword>IRDye800</keyword>
  <keyword>NIRF</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

